Create account

Coverage dated November 5, 2026 to November 6, 2026

Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma

Headline from Geneng News

"Two cases to date have shown evidence of vector integration into the DNA of the patients. In both cases, the patients underwent treatment and continue to be monitored,” Novartis said in a statement.

Geneng News's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

4 articles, oldest first.

  1. STAT

    STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy (opens STAT)

    Published

    STAT's feed description

    Novartis has acknowledged seven previously unknown instances in which tumors were found in children who were treated with its spinal muscular atrophy therapy, Zolgensma.

  2. STAT

    STAT+: Pharmalittle: We’re reading about a Novartis gene therapy, faster U.K. drug reviews, and more (opens STAT)

    Published

    STAT's feed description

    Novartis acknowledged seven instances of tumors being found in children who were treated with Zolgensma for spinal muscular atrophy

  3. STAT

    STAT+: New tumor cases show common gene therapy tool can come with risk (opens STAT)

    Published

    STAT's feed description

    New cases show AAV gene therapies like Zolgensma carry tumor risks, raising key concerns for SMA patients and gene therapy researchers in general.

  4. Geneng News

    Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma (opens Geneng News)

    Published

    Geneng News's feed description

    "Two cases to date have shown evidence of vector integration into the DNA of the patients. In both cases, the patients underwent treatment and continue to be monitored,” Novartis said in a statement.